E-Mail
IMAGE: Control mice (left panel) with prostate cancer show large areas of metastasis in the lungs (blue). When a subset of animals were treated with unmodified T cells (middle panel), the. view more
Credit: Shawn Wang, Ph.D.
Through T cell engineering, researchers at Virginia Commonwealth University Massey Cancer Center show that it s possible to arrest tumor growth for a variety of cancers and squash the spread of cancer to other tissues. This research will be published in tomorrow s print edition of
Cancer Research.
The paper builds on decades of research by study co-senior author Paul B. Fisher, M.Ph., Ph.D., a member of Massey s Cancer Biology research program, who discovered a protein called IL-24 that attacks a variety of cancers in several different ways.
E-Mail
NEW YORK, NY (April 29, 2021) A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung, revealing mechanisms that result in lethal COVID-19, and may explain long-term complications and show how COVID-19 differs from other infectious diseases.
Led by researchers at Columbia University Vagelos College of Physicians and Surgeons and Herbert Irving Comprehensive Cancer Center, the study found that in patients who died of the infection, COVID-19 unleashed a detrimental trifecta of runaway inflammation, direct destruction and impaired regeneration of lung cells involved in gas exchange, and accelerated lung scarring.
Though the study looked at lungs from patients who had died of the disease, it provides solid leads as to why survivors of severe COVID may experience long-term respiratory complications due to lung scarring.
Fasting lowers blood pressure by reshaping the gut microbiota eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Related Company:
Vermont Business Magazine The Robert Larner, MD College of Medicine at The University of Vermont (UVM), in collaboration with the UVM Health Network (UVMHN) and the UVM Medical Center, has announced that Randall F Holcombe, MD, MBA, has been appointed director of the UVM Cancer Center (UVMCC) and chief of the Division of Hematology and Oncology in the Department of Medicine. Holcombe is expected to hold the newly established J Walter Juckett Chair in Cancer Research. He joins UVM and UVMHN from the National Cancer Institute (NCI)-designated University of Hawai i Cancer Center, where he has served as director since 2016.
E-Mail
IMAGE: A preclinical study shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using. view more
Credit: MD Anderson Cancer Center
Abstract #LB008
HOUSTON A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins through a Bicycle toxin conjugate (BTC), shows encouraging results for the treatment of osteosarcoma.